BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+13.23%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$12.1B
AUM Growth
+$12.1B
(+12%)
Cap. Flow
+$191M
Cap. Flow
% of AUM
1.58%
Top 10 Holdings %
Top 10 Hldgs %
75.84%
Holding
140
New
5
Increased
25
Reduced
5
Closed
7
Top Buys
| 1 |
ACOR
Acorda Therapeutics, Inc.
ACOR
|
$106M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$56.7M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
$28.2M |
| 4 |
Alkermes
ALKS
|
$19.9M |
| 5 |
AAAP
Advanced Accelerator Applications S.A. American Depositary Shares
AAAP
|
$17.7M |
Top Sells
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$18.6M |
| 2 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$16.8M |
| 3 |
XNPT
XENOPORT, INC.
XNPT
|
$16.7M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
$14.5M |
| 5 |
Larimar Therapeutics
LRMR
|
$12.5M |
Sector Composition
| 1 | Healthcare | 73.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $2.11B | 17.5% | 19,475,316 +347 | +0% | +$37.6K |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.67B | 13.87% | 37,293,728 +1,263,982 | +4% | +$56.7M |
|
|
ALXN
3
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $1.25B | 10.34% | 6,542,599 | – | – |
|
4
AbbVie
ABBV
$372B
| $851M | 7.05% | 14,373,538 | – | – |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $730M | 6.05% | 20,481,442 | – | – |
|
|
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
| $481M | 3.98% | 13,659,264 +936 | +0% | +$32.9K |
|
|
ANAC
7
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $474M | 3.93% | 4,198,520 +63,108 | +2% | +$7.13M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $431M | 3.57% | 4,115,083 +38,730 | +1% | +$4.06M |
|
|
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
| $313M | 2.59% | 8,310,017 +748,537 | +10% | +$28.2M |
|
|
DBVT
10
DBV Technologies
DBVT
$264M
| $198M | 1.64% | 5,462,019 | – | – |
|
|
ACOR
11
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $153M | 1.27% | 3,580,112 +2,483,236 | +226% | +$106M |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $147M | 1.22% | 14,217,779 +107,600 | +0.8% | +$1.11M |
|
|
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $98.6M | 0.82% | 4,865,647 +675,053 | +16% | +$13.7M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $93.4M | 0.77% | 2,955,074 | – | – |
|
15
Cerus
CERS
$251M
| $85.7M | 0.71% | 13,553,275 | – | – |
|
16
Neurogene
NGNE
$264M
| $84.2M | 0.7% | 6,747,332 | – | – |
|
17
Heron Therapeutics
HRTX
$207M
| $77.6M | 0.64% | 2,907,784 | – | – |
|
|
IMGN
18
DELISTED
Immunogen Inc
IMGN
| $60.4M | 0.5% | 4,452,445 +904,405 | +25% | +$12.3M |
|
|
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $57.2M | 0.47% | 1,262,382 | – | – |
|
|
NVTA
20
DELISTED
Invitae Corporation
NVTA
| $53.8M | 0.45% | 6,554,967 | – | – |
|
21
Neurocrine Biosciences
NBIX
$13.8B
| $48.1M | 0.4% | 850,739 +100,000 | +13% | +$5.66M |
|
|
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
| $40.2M | 0.33% | 3,241,783 | – | – |
|
23
Sangamo Therapeutics
SGMO
$157M
| $37M | 0.31% | 4,055,876 +300,000 | +8% | +$2.74M |
|
24
Halozyme
HALO
$8.56B
| $33.5M | 0.28% | 1,931,057 | – | – |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $32.8M | 0.27% | 609,166 | – | – |
|